David Fallace, J.D. / M.B.A.

Mr. Fallace (Dave) is a Managing Partner and Co-Founder of Cure Ventures. He has made investments in venture capital and alternative asset funds for over 20 years. He served as a member of the investment committee of several large multibillion-dollar firms overseeing alternative investment portfolios. Across these portfolios he made investments as a limited partner and as a founding investor in start-ups.

Most recently, Dave served as an advisor for the biotech venture capital fund Polaris Partners where he evaluated Biotechnology and Health Care Information Technologies investments. During this period, he also served as an Expert-in-Resident program at Harvard University’s Office of Technology Development. Prior to Polaris, he served as a Managing Director and member of the investment committee heading the $2.5 billion diversifying strategies at TIFF Investment Management.

From 2013 to 2016, Dave served as the Director of Investments leading the $10 billion Special Opportunities program at the Alaska Permanent Fund Corporation. He spearheaded their direct venture investing serving as a board observer at Juno Therapeutics (Acquired by Celgene), and Denali Therapeutics (NASDAQ: DNLI).

Starting in 2000, Dave worked at GF Private Equity Group managing private equity and hedge fund portfolios in addition to investing in direct venture capital transactions. He served on the board or board observer of Ahura (Acquired Thermo Fisher), Alfalight (Acquired Gooch & Housego), Kotura (Acquired Mellanox), Pathscale (Acquired QLogic), Teros (Acquired Citrix), and Impinj (NASDAQ:PI).

Dave received his B.A. from Stony Brook University and his M.B.A. and J.D. from the State University of New York at Buffalo focusing on tax and financial structuring and is a member of the New York Bar.